Lane-Reticker SK, Manguso RT, Haining WN. Pooled in vivo screens for cancer immunotherapy target discovery. Immunotherapy 2018;10:167–170.
Manguso RT, Pope HW, Zimmer MD, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547:413–418.
Juneja VR, McGuire KA, Manguso RT, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214:895–904.
Robert Manguso is the group leader of the Tumor Immunotherapy Discovery Engine (TIDE) project, a new initiative within the Cancer Program of the Broad Institute of MIT and Harvard. His group uses in vivo CRISPR-based screens to identify new therapeutic targets for combination with existing immunotherapies and to determine the mechanisms by which tumor cells evade immunotherapy. An expert in genetic manipulation of transplantable tumor models, Manguso is interested in applying modern genetic tools to the field of cancer immunology to understand why immunotherapy fails.
Manguso joined the Broad Institute 2017 after completing his doctoral studies in Nicholas Haining’s lab at the Dana-Farber Cancer Institute and Harvard Medical School. He was awarded a Fulbright scholarship in 2011, allowing him to undertake research in Lotte Pedersen’s lab at the University of Copenhagen, and he holds a B.A. from Wheaton College in Norton, Massachusetts.
Contact Robert Manguso via email at email@example.com.